Einträge von Schade-Brittinger, C. auf dem Publikationsserver

Fensterer, H., Schade-Brittinger, C., Müller, H.-H., Tebbe, S., Fass, J., Lindig, U., Settmacher, U., Schmidt, W.E., Märten, A., Ebert, M.P., Kornmann, M., Hofheinz, R., Endlicher, E., Brendel, C., Barth, P.J., Bartsch, D.K., Michl, P. und Gress, T.M. (2013) Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP). Annals of Oncology 24 (10), S. 2576-2581. Volltext nicht vorhanden.

Rosenow, F., Schade-Brittinger, C., Burchardi, N., Arnold, Stephan, LaLiMo Study Group, , make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference , make_name_string expected hash reference, make_name_string expected hash reference und make_name_string expected hash reference (2012) The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy—an open-label, prospective, randomised controlled multicenter study. Journal of Neurology, Neurosurgery and Psychiatry 83, S. 1093-1098.

Fensterer, H., Schade-Brittinger, C., Mueller, H., Schupfner, B., Fass, J., Lindig, U., Settmacher, U., Ebert, M. P., Kornmann, M., Hofheinz, R., Endlicher, E., Brendel, C., Barth, P. J., Bartsch, D. K. und Gress, T. M. (2011) Multicenter phase II trial to investigate safety and efficacy of an adjuvant therapy with gemcitabine and cetuximab in patients with R0 or R1 resected pancreatic cancer. Journal of Clinical Oncology 29 (15_sup), S. 4039. Volltext nicht vorhanden.